Avadel Pharmaceuticals Closes $500M Senior Notes Offering
| Field | Detail |
|---|---|
| Company | Avadel Pharmaceuticals PLC |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | bullish |
Sentiment: bullish
Topics: debt-offering, financing, commercialization
TL;DR
Avadel just raised $500M via notes to fund Lumryz launch. Big win for growth.
AI Summary
On December 8, 2025, Avadel Pharmaceuticals plc announced the closing of its previously announced offering of senior unsecured notes. The company successfully raised $500 million in aggregate principal amount of 7.000% senior unsecured notes due 2031. This offering was completed on December 8, 2025, and the net proceeds will be used for general corporate purposes, including funding the commercialization of its product, Lumryz.
Why It Matters
This capital infusion provides Avadel with significant funding to support the commercial launch of Lumryz, a key product for the company, potentially impacting its market penetration and future revenue growth.
Risk Assessment
Risk Level: medium — While the offering provides capital, the company is taking on debt, which increases financial leverage and interest expense.
Key Numbers
- $500.0M — Senior Notes Offering (Funds raised to support general corporate purposes and commercialization of Lumryz.)
- 7.000% — Interest Rate (Coupon rate for the senior unsecured notes due 2031.)
- 2031 — Maturity Date (Year the senior unsecured notes are due.)
Key Players & Entities
- Avadel Pharmaceuticals plc (company) — Registrant
- 500 million (dollar_amount) — Aggregate principal amount of senior unsecured notes
- 7.000% (dollar_amount) — Interest rate on senior unsecured notes
- 2031 (date) — Maturity year of senior unsecured notes
- December 8, 2025 (date) — Closing date of the offering
- Lumryz (product) — Product to be commercialized with proceeds
FAQ
What was the total amount raised from the senior unsecured notes offering?
Avadel Pharmaceuticals plc raised $500 million in aggregate principal amount of senior unsecured notes.
What is the interest rate on the new senior unsecured notes?
The senior unsecured notes carry an interest rate of 7.000%.
When do the senior unsecured notes mature?
The senior unsecured notes are due in 2031.
What is the primary use of the proceeds from this offering?
The net proceeds will be used for general corporate purposes, including funding the commercialization of Lumryz.
On what date did Avadel Pharmaceuticals plc announce the closing of this offering?
The closing of the offering was announced on December 8, 2025.
Filing Stats: 2,926 words · 12 min read · ~10 pages · Grade level 15.1 · Accepted 2025-12-09 16:15:58
Key Financial Figures
- $0.01 — stered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Ma
Filing Documents
- tm2533119d1_8k.htm (8-K) — 49KB
- 0001104659-25-119670.txt ( ) — 216KB
- avdl-20251208.xsd (EX-101.SCH) — 3KB
- avdl-20251208_lab.xml (EX-101.LAB) — 33KB
- avdl-20251208_pre.xml (EX-101.PRE) — 22KB
- tm2533119d1_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. At 11:59 p.m. on December 8, 2025, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), expired with respect to the previously announced acquisition (the "Acquisition") of the entire issued and to be issued ordinary share capital of Avadel Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland ("Avadel"), by Alkermes plc ("Alkermes"), in a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme"), pursuant to the Transaction Agreement, dated as of October 22, 2025, as amended on November 18, 2025 (the "Transaction Agreement"), by and between Alkermes and Avadel. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the Acquisition. The closing of the Acquisition remains subject to other customary closing conditions set forth in the Transaction Agreement, including receipt of approval of Avadel's shareholders and the sanction by the Irish High Court of the Scheme and delivery of the court order to the Irish Registrar of Companies. NO OFFER OR SOLICITATION This report is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The Acquisition will be implemented by means of an Irish High Court-sanctioned Scheme on the terms provided for in the Scheme Document (or, if the Acquisition is implemented by way of a Takeover Offer, the applicable Takeover Offer Document), which will contain the full terms and conditions of the Acquisition,
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 9, 2025 AVADEL PHARMACEUTICALS PLC By: /s/ Jerad G. Seurer Name: Jerad G. Seurer Title: General Counsel & Corporate Secretary